DekaBank Deutsche Girozentrale bought a new position in GT Biopharma, Inc. (NASDAQ:GTBP – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned approximately 77.02% of GT Biopharma at the end of the most recent reporting period.
GT Biopharma Stock Down 1.6 %
GT Biopharma stock traded down $0.04 during mid-day trading on Friday, hitting $2.51. The company’s stock had a trading volume of 9,200 shares, compared to its average volume of 13,515. GT Biopharma, Inc. has a 52-week low of $2.48 and a 52-week high of $10.66. The firm’s 50 day moving average is $2.97 and its 200 day moving average is $3.92.
GT Biopharma (NASDAQ:GTBP – Get Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($2.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.70) by $0.58.
About GT Biopharma
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
Featured Stories
- Five stocks we like better than GT Biopharma
- Do ETFs Pay Dividends? What You Need to Know
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Using the MarketBeat Stock Split Calculator
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.